AbelZeta Pharma, a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, has received the US Food and Drug Administration (FDA) clearance under its regenerative medicine advanced therapy (RMAT) designation regarding the multiple-centre registrational phase 2 clinical trial for C-CAR168, an anti-CD20/BCMA bispecific CAR-T, in the treatment of patients with lupus nephritis (LN) refractory to standard therapy.
The phase 2 trial will further evaluate the safety and efficacy of C-CAR168 in this patient population with significant unmet medical needs.
